Morphopathological and immunohistochemical features of a pure mucinous breast carcinoma – Case report

1. Ferlay, J., Soerjomataram, I., Ervik, M., et al. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer. Retrieved March 3, 2016 from: http://globocan.iarc.frSearch in Google Scholar

2. Global Cancer Facts & Figures 3rd Edition. Retrieved March 5, 2016 from http://www.cancer.org/acs/groups/content/@research/Search in Google Scholar

3. Bussolati, G. & Sapino, A. (2012). Mucinous carcinoma and carcinoma with signet-ring-cell differentiation. In Lakhani S., Ellis I., Schnitt S., et al. (Eds.) WHO Classification of Tumours of the Breast 4^th ed. (pp 60-61). Lyon: IARC Press.Search in Google Scholar

4. Cao, A.Y., He, M., Liu, Z.B., Di, G.H., Wu, J., Lu, J.S., Liu, G.Y., Shen, Z.Z. & Shao, Z.M. (2012). Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China. Ann Surg Oncol. Sep 19(9):3019-27. doi: 10.1245/s10434-012-2322-6. 19:3019–3027.10.1245/s10434-012-2322-6Search in Google Scholar

5. Bae, S.Y., Choi, M.Y., Cho, D.H., et al. (2011). Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis. J Breast Cancer. 14:308–13. doi: 10.4048/jbc.2011.14.4.308.10.4048/jbc.2011.14.4.308Search in Google Scholar

6. Sahoo, S. & Shin, S.J. (2012). Special types of breast carcinoma: tubular carcinoma, mucinous carcinoma, cribriform carcinoma, invasive micropapillary carcinoma and medullary carcinoma. In Dabbs DJ. Breast pathology. (pp 536-572). Elsevie Saunder.Search in Google Scholar

7. Kashiwagi, S., Onoda, N., Asano, Y., Kawajiri, H., Takashima, T., Ohsawa, M., et al. (2013). Clinical significance of the subclassification of 71 cases mucinous breast carcinoma. Springer plus. 2:481-86.Search in Google Scholar

8. Corben, A.D. & Brogi, E. (2014) Mucinous carcinoma. In Hoda, S.A., Brogi, E., Koerner, F.C. & Rosen, PP. (Eds.) Rosen’s breast pathology–fourth edition. (pp 611-644). Philadelphia: Lippincott Williams & Wilkins.Search in Google Scholar

9. Elston, C.W. & Ellis, I.O. (1991). Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19 (5): 403-10.Search in Google Scholar

10. Hammond, M.E., Hayes, D.F., Allred, D.C., Dowsett, M., Hagerty, KL., Badve, S., et al. (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Arch Pathol Lab Med. 134(7):e48-e72.Search in Google Scholar

11. Dowsett, M., Nielsen, T.O., A’Hern, R., Bartlett, J., Coombes, C., Cuzick, J., Ellis, M. et al. (2011). Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 103(22):1656-1664.Search in Google Scholar

12. Wolff, A.C., Hammond, M.E., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H. et al. (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi: 10.1200/JCO.2013.50.9984.10.1200/JCO.2013.50.9984Search in Google Scholar

13. Di Saverio, S., Gutierrez, J. & Avisar, E. (2008). A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 111:541-547.Search in Google Scholar

14. Sahoo, S. & Shin, S.J. (2012) Special types of breast carcinoma: tubular carcinoma, mucinous carcinoma, cribriform carcinoma, invasive micropapollary carcinoma and medullary carcinoma. In Dabbs DJ.(Eds) Breast pathology. (pp 536-572). Elsevier Saunders10.1016/B978-1-4377-0604-8.00029-1Search in Google Scholar

15. Ishikawa, T., Hamaguchi, Y., Ichikawa, Y. et al. (2002). Locally advanced mucinous carcinoma of the breast with sudden growth acceleration: a case report. Jpn J Clin Onc. 32:64-67.Search in Google Scholar

16. Scopsi, L., Andreola, S., Pilotti, S., et al (1994). Mucinous carcinoma of the breast. A clinicopathologic, histochemical, and immunocytochemical study with special reference to neuroendocrine differentiation. Am J Surg Pathol. 18:702-711.Search in Google Scholar

17. Ranade, A., Batra, R., Sandhu, G., et al (2010). Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micro papillary pattern. J Clin Pathol. 63:1043-1047.Search in Google Scholar

18. Diab, S.G., Clark, G.M., Osborne, C.K., et al (1999). Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 17:1442-144810.1200/JCO.1999.17.5.1442Search in Google Scholar

19. Fentiman, I.S., Millis, R.R., Smith, P., et al. (1997) Mucoid breast carcinomas: histology and prognosis. Br T Cancer. 75:1061-1065.10.1038/bjc.1997.180Search in Google Scholar

20. Gadre, S.A., Perkins, G.H., Sabin, A.A., et al. (2008) Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion. Histopathology. 53:545-553.10.1111/j.1365-2559.2008.03152.xSearch in Google Scholar

21. Slodkowska, E., Corben, A.D., Catalano, J.P., et al (2012). Pure mucinous carcinoma in women 40 years old or younger: clinicopathological and follow-up study. USCAP Meeting Vancouver Canada, March 2012.Search in Google Scholar

22. Lacroix-Triki, M., Suarez, P.H., MacKay, A., et al. (2010). Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol. 222:282-298.Search in Google Scholar

23. Park, S., Koo, J., Park, H.S., et al. (2010) Expression of androgen receptors in primary breast cancer. Ann Oncol. 21:488-492.10.1093/annonc/mdp510Search in Google Scholar

24. Cho, L.C. & Hsu, Y.H. (2008) Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast. Kaohsiung I Med Sci. 24:227-23210.1016/S1607-551X(08)70146-3Search in Google Scholar

25. Rauch, G.M., Kuerer, H.M., Scoggins, M.E., Fox, P.S., et al (2013). Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast byestrogen receptor status. Breast Cancer Res Treat 139:639–647. doi:10.1007/s10549-013-2598-7.10.1007/s10549-013-2598-7398279623774990Search in Google Scholar

26. Lari, S.A. & Kuerer, H.M. (2011) Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2:232-261. doi:10.7150/jca.2.232.10.7150/jca.2.232Search in Google Scholar

27. Walker, R.A., Hanby, A., Pinder, S.E., et al.(2012) Current issues in diagnostic breast pathology. J Clin Pathol. 65:771-78510.1136/jclinpath-2012-200733Search in Google Scholar

28. Allred, D.C., Bryant, J., Land, S., et al. (2002) Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP protocol B-24. Breast Cancer Res. Treat. 76 (Suppl. 1), (abstract 30).Search in Google Scholar

29. Roka, S., Rodas, M., Taucher, S., et al. (2004) High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol. 30:243-247.10.1016/j.ejso.2003.11.004Search in Google Scholar

30. Wiechmann, L. & Kuerer, H.M. (2008). The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 112:2130–2142. doi:10.1002/cncr.23430.10.1002/cncr.23430Search in Google Scholar

31. Williams, K.E., Barnes, N.L.P., Cramer, A., Johnson, R., et al (2015) Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol. 26(5):1019-102510.1093/annonc/mdv062Search in Google Scholar

32. Lohrisch, C. & Piccart, M. (2001) An overview of HER2. Semin Oncol. 28:3–31.10.1016/S0093-7754(01)90103-4Search in Google Scholar

33. Latta, E.K., Tjan, S., Parkes, R.K. & O’Malley, F.P. (2002) The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 15:1318–25.10.1097/01.MP.0000038462.62634.B112481013Search in Google Scholar

34. Borgquist, S., Zhou, W., Jirström, K., Amini, R.M., Sollie, T., Sørlie, T., et al (2015). The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer. Jun 11;15:468. doi: 10.1186/s12885-015-1479-3.10.1186/s12885-015-1479-3446471326062614Search in Google Scholar

35. Hoque A, Sneige N, Sahin AA. (2002). Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 11:587–590.Search in Google Scholar

36. Bockstal MV., Lambein K., Denys H., Braems G. et al. (2014) Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype. Virchows Arch. 465:275–289; doi 10.1007/s00428-014-1609-3Search in Google Scholar